Exenatide was among the first GLP-1 agonists introduced to clinical practice
5 WARNINGS AND PRECAUTIONS WARNINGS AND PRECAUTIONS SECTION 6 ADVERSE REACTIONS ADVERSE REACTIONS SECTION The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions ( 5.1 )] Acute Pancreatitis [see Warnings and Precautions ( 5.2 )] Acute Gallbladder Disease [see Warnings and Precautions ( 5.3 )] Hypoglycemia [see Warnings and Precautions ( 5.4 )] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions ( 5.5 )] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions ( 5.6 )] Hypersensitivity Reactions [see Warnings and Precautions ( 5.7 )] Diabetic Retinopathy Complications in Patients with Type 2 Diabetes [see Warnings and Precautions ( 5.8 )] Heart Rate Increase [see Warnings and Precautions ( 5.9 )] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions ( 5.10 )] 7 DRUG INTERACTIONS DRUG INTERACTIONS SECTION 8 USE IN SPECIFIC POPULATIONS USE IN SPECIFIC POPULATIONS SECTION 10 OVERDOSAGE OVERDOSAGE SECTION Overdoses have been reported with other GLP-1 receptor agonists
The CREDENCE trial enrolled 4,401 participants with type 2 diabetes mellitus and CKD, with a mean eGFR of 56.2 mL/min/1.73 m 2 and a median urinary albumin-to-creatinine ratio (UACR) of 927 mg/g (Table 1, Fig
Ann Allergy Asthma Immunol 2007;99(1):82-6 2) Cox L, Larenas-Linnemann D, Lockey RF, et al
Mild cases will generally resolve with discontinuation of the drug
Maintaining good oral hygiene is vitalbrushing your teeth regularly and staying hydrated can help manage these challenges
